title: [Pharmacokinetics of bacteria bioleaching solution of realgar in rat].
abstract: The paper is to report the preparation of realgar bioleaching solution (RBS) by bacteria and the comparison of pharmacokinetics of RBS and H3AsO3 (ATO), and the study of its possible change of absorption and distribution of soluble arsenic in rat. The experiment was carried out on Wistar rats given peritoneal injection of RBS at a dose of 0.3 mg x kg(-1) (soluble arsenic content, 0.3 mg x kg(-1)), and rats given ATO at the dose of 0.3 mg x kg(-1) (soluble arsenic content, 0.3 mg x kg(-1)). The arsenic concentrations in many tissues including heart, liver, spleen, lung, renal and brain were determined. The changes of pharmacokinetic parameters and arsenic distribution in different tissues were detected and compared in these two groups of rats. The pharmacokinetic parameters of RBS and ATO are very similar. There is very few distribution of arsenic in the tissues in RBS group, compared with the ATO group. There is significant difference in the content of arsenic between two groups statistically (P < 0.01). It is feasible that we select the bacteria bioleaching solution as a candidate drug, which may be employed for primary change of arsenic compounds including dissolved inorganic arsenic and organic arsenic, in order to improve bioavailability and decrease the amount of arsenic accumulation in animal tissues. In addition, there is significant difference in the change of arsenic compounds between two groups. It can be concluded that, the investigation on application of microbial technology may provide a basis for exploratory research of realgar.
authors.affiliation: College of Life Science, Lanzhou University, Lanzhou 730000, China. zjh@hqu.edu.cn
authors.forename: Jing-hong
authors.initials: JH
authors.lastname: Zhang
authors.forename: Qin
authors.initials: Q
authors.lastname: Fan
authors.forename: Hong-yu
authors.initials: HY
authors.lastname: Li
mesh_terms: D000818:Animals; D019540:Area Under Curve; D001149:Arsenates / Q000493:pharmacokinetics; D001151:Arsenic / Q000378:metabolism*; D001152:Arsenicals / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001419:Bacteria / Q000378:metabolism*; D019075:Electrophoresis, Capillary / Q000379:methods; D005260:Female; D007274:Injections, Intraperitoneal; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012996:Solutions; D013440:Sulfides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013810:Therapeutic Equivalency; D014018:Tissue Distribution
chemical_list: D001149:Arsenates; D001152:Arsenicals; D012996:Solutions; D013440:Sulfides; C058317:arsenic disulfide; D001151:Arsenic; C025657:arsenic acid